CanSino Biologics (SHSE:688185) EPS (Basic): ¥0.16 (TTM As of Dec. 2025)


SHSE:688185 CanSino Biologics Inc SHSE:688185
70 GF Score
Price ¥49.94
GF Value ¥111.01
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is CanSino Biologics EPS (Basic)?

CanSino Biologics SHSE:688185 -2.58% 70 EPS (Basic) is ¥0.16 as of Dec. 2025. GuruFocus rates SHSE:688185 with a GF Score™ of 70/100 and a GF Value™ of ¥111.01 (Significantly Undervalued). The stock has 3 warning signs investors should review.

CanSino Biologics's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was ¥0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.16.

CanSino Biologics's EPS (Diluted) for the three months ended in Dec. 2025 was ¥0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ¥0.16.

CanSino Biologics's EPS without NRI for the three months ended in Dec. 2025 was ¥-0.08. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.12.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, CanSino Biologics's highest 3-Year average EPS without NRI Growth Rate was -44.60% per year. The lowest was -75.40% per year. And the median was -60.20% per year.

CanSino Biologics  (SHSE:688185) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

CanSino Biologics EPS (Basic) Related Terms

CanSino Biologics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for CanSino Biologics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics EPS (Basic) Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.74 -3.68 -6.01 -1.53 0.11

CanSino Biologics Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 0.00 0.00 0.11 0.05
SHSE:688185
70GF Score
CanSino Biologics Inc SHSE:688185
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanSino Biologics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

CanSino Biologics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(27.873-0)/247.006
=0.11

CanSino Biologics's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(13.433-0)/247.006
=0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ¥0.16 mean?
CanSino Biologics (SHSE:688185) has a EPS (Basic) of ¥0.16 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CanSino Biologics and its competitors.
Is CanSino Biologics' EPS (Basic) too high?
CanSino Biologics' current EPS (Basic) is ¥0.16. Overall, CanSino Biologics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' EPS (Basic) compare to ZTS?
CanSino Biologics' EPS (Basic) of ¥0.16 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on CanSino Biologics and its competitors. CanSino Biologics's current EPS (Basic) is ¥0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (SHSE:688185) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥111.01, compared to a current price of ¥49.94 — trading 55% below its estimated fair value. The current EPS (Basic) is ¥0.16. CanSino Biologics' overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For CanSino Biologics (SHSE:688185), the current EPS (Basic) is ¥0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CanSino Biologics (SHSE:688185) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of ¥49.94 is trading 55% below its estimated GF Value™ of ¥111.01. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for SHSE:688185:

  • EPS (Basic): ¥0.16
  • GF Value™: ¥111.01 vs. price of ¥49.94 (55% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the SHSE:688185 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
70GF Score

Get the complete analysis for SHSE:688185

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥49.94
Price
¥111.01
GF Value